CEMI Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (27 apr 2023 @ 22:00):

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases...

Stats
Dagens volum	351 642
Gjennomsnittsvolum	538 392
Markedsverdi	16.71M
EPS	$0 ( 2024-03-27 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.632
ATR14	$0.0250 (5.49%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-11	Angelico Paul	Buy	29 333	Common Stock
2023-03-15	Angelico Paul	Buy	7 885	Common Stock
2023-03-15	Angelico Paul	Sell	2 843	Common Stock
2023-03-11	Angelico Paul	Sell	10 575	Common Stock
2023-03-11	Angelico Paul	Sell	29 333	Restricted stock units

INSIDER POWER
-90.31
Last 100 transactions
Buy: 781 277 \| Sell: 10 790 554

Volum Korrelasjon

Lang: 0.06 (neutral)

Kort: 0.14 (neutral)

Signal:(58.078) Neutral

Chembio Diagnostics Inc Korrelasjon

10 Mest positive korrelasjoner
EWCZ	0.948
FTDR	0.94
NPCE	0.938
HEWG	0.937
DXGE	0.932
ULTA	0.931
ROBT	0.916
GLBE	0.916
NRC	0.912
WYNN	0.91

10 Mest negative korrelasjoner
ADXN	-0.922
MNSB	-0.912
PRSO	-0.912
GLBS	-0.91
WALD	-0.908
PLL	-0.906
VNET	-0.904
STRS	-0.903
SIFY	-0.902
KBWY	-0.9

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Chembio Diagnostics Inc Korrelasjon - Valuta/Råvare

0.54
( weak )

0.64
( weak )

0.00
( neutral )

0.43
( neutral )

-0.38
( neutral )

-0.51
( weak negative )

Chembio Diagnostics Inc Økonomi

Annual	2022
Omsetning:	$48.34M
Bruttogevinst:	$9.76M (20.19 %)
EPS:	$-0.960

FY	2022
Omsetning:	$48.34M
Bruttogevinst:	$9.76M (20.19 %)
EPS:	$-0.960

FY	2021
Omsetning:	$47.82M
Bruttogevinst:	$13.32M (27.86 %)
EPS:	$-1.400

FY	2020
Omsetning:	$30.45M
Bruttogevinst:	$6.58M (21.60 %)
EPS:	$-1.340

Financial Reports:

No articles found.

Chembio Diagnostics Inc

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.